Home Other Building Blocks 2438-72-4
2438-72-4,MFCD00078936
Catalog No.:AA007NJI

2438-72-4 | Bufexamac

Pack Size
Purity
Availability
Price(USD)
Quantity
  
100mg
98%
in stock  
$6.00   $4.00
- +
250mg
98%
in stock  
$11.00   $8.00
- +
1g
98%
in stock  
$13.00   $9.00
- +
5g
98%
in stock  
$50.00   $35.00
- +
25g
98%
in stock  
$77.00   $54.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA007NJI
Chemical Name:
Bufexamac
CAS Number:
2438-72-4
Molecular Formula:
C12H17NO3
Molecular Weight:
223.2683
MDL Number:
MFCD00078936
SMILES:
CCCCOc1ccc(cc1)CC(=O)NO
NSC Number:
758153
Properties
Computed Properties
 
Complexity:
200  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
16  
Hydrogen Bond Acceptor Count:
3  
Hydrogen Bond Donor Count:
2  
Rotatable Bond Count:
6  
XLogP3:
1.9  

Literature

Title: Development and therapeutic implications of selective histone deacetylase 6 inhibitors.

Journal: Journal of medicinal chemistry 20130822

Title: Allergic contact dermatitis to topical preparations of bufexamac.

Journal: The Australasian journal of dermatology 20120801

Title: Contact dermatitis caused by bufexamac sparing the eruption of herpes zoster.

Journal: The Journal of dermatology 20120401

Title: Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors.

Journal: Clinical epigenetics 20120101

Title: Allergic contact dermatitis syndrome from bufexamac for nursing infant.

Journal: Dermatitis : contact, atopic, occupational, drug 20120101

Title: In vitro photobiochemical characterization of sulfobutylether-β-cyclodextrin formulation of bufexamac.

Journal: Journal of pharmaceutical and biomedical analysis 20110601

Title: EMA revokes marketing authorization for bufexamac.

Journal: Contact dermatitis 20110401

Title: Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes.

Journal: Nature biotechnology 20110301

Title: Contact sensitization in the anal and genital area.

Journal: Current problems in dermatology 20110101

Title: Homing and reparative effect of intra-articular injection of autologus mesenchymal stem cells in osteoarthritic animal model.

Journal: BMC musculoskeletal disorders 20110101

Title: Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

Journal: Bioorganic & medicinal chemistry letters 20101101

Title: Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.

Journal: Antimicrobial agents and chemotherapy 20100901

Title: Contact dermatitis due to topical drugs.

Journal: Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 20091001

Title: [Bufexamac-induced pigmented purpuric eruption].

Journal: Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20090501

Title: Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: a study in 641 children.

Journal: Allergy 20090501

Title: A systematic review of randomized controlled trials of treatments for inherited forms of epidermolysis bullosa.

Journal: Clinical and experimental dermatology 20090101

Title: [Facial allergic contact dermatitis. Data from the IVDK and review of literature].

Journal: Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20090101

Title: Allergic contact dermatitis to topical drugs--epidemiological risk assessment.

Journal: Pharmacoepidemiology and drug safety 20080801

Title: Acute generalized exanthematous pustulosis induced by bufexamac in an atopic girl.

Journal: Contact dermatitis 20080401

Title: Non-steroidal anti-inflammatory drugs selectively inhibit cytokine production by NK cells and gamma delta T cells.

Journal: Experimental dermatology 20061201

Title: Changes in MMP-2 and -9 activity and MMP-8 reactivity after amphotericin B induced synovitis and treatment with bufexamac.

Journal: Journal of veterinary medicine. A, Physiology, pathology, clinical medicine 20060801

Title: Microsphere-based protease assays and screening application for lethal factor and factor Xa.

Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

Title: Type-IV sensitization profile of individuals with atopic eczema: results from the Information Network of Departments of Dermatology (IVDK) and the German Contact Dermatitis Research Group (DKG).

Journal: Allergy 20060501

Title: Chronic urticaria due to Blastocystis hominis.

Journal: The Australasian journal of dermatology 20060501

Title: [A common and insidious side-effect: allergic contact dermatitis caused by bufexamac used in the treatment of dermatitis. Results from the Information Network of Departments of Dermatology (IDVK)].

Journal: Deutsche medizinische Wochenschrift (1946) 20051216

Title: [Anogenital dermatoses--allergic and irritative causative factors. Analysis of IVDK data and review of the literature].

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 20051201

Title: Screening for new antioxidative compounds for topical administration using skin lipid model systems.

Journal: Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20050915

Title: Frequency of contact allergy in German children and adolescents patch tested between 1995 and 2002: results from the Information Network of Departments of Dermatology and the German Contact Dermatitis Research Group.

Journal: Contact dermatitis 20040901

Title: Allergic contact dermatitis with spreading over extensive regions due to topical use of 5% bufexamac ointment.

Journal: The Journal of dermatology 20040201

Title: Examinations of the antioxidative properties of the topically administered drug bufexamac reveal new insights into its mechanism of action.

Journal: The Journal of pharmacy and pharmacology 20031001

Title: [Epidemiologic surveillance of contact allergens. The 'monitoring series' of IVDK (Information Network ofDermatologic Clinics for Detection and Scientific Evaluation of Contact Allergy].

Journal: Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20030801

Title: [Severe allergic contact dermatitis with generalized spread due to bufexamac presenting as the 'baboon' syndrome].

Journal: Deutsche medizinische Wochenschrift (1946) 20030314

Title: An integrative approach to eczema (atopic dermatitis).

Journal: Holistic nursing practice 20030101

Title: [Retrospective of national pharmacovigilance surveys on drug-induced bullous, vesicular eruptions: methods and results ].

Journal: Therapie 20020101

Title: [Mastu S - a new antihemorrhoidal cream for pregnant women].

Journal: Akusherstvo i ginekologiia 20020101

Title: Effects of intra-articular injections of bufexamac suspension in healthy horses.

Journal: American journal of veterinary research 20011001

Title: [Dermatological local therapy. How to control eczema].

Journal: MMW Fortschritte der Medizin 20010614

Title: Skin sensitizing properties of arylalcanoic acids and their analogues.

Journal: Contact dermatitis 19790901

Title: Bufexamac: a review of its pharmacological properties and therapeutic efficacy in inflammatory dermatoses.

Journal: Drugs 19750101

Title: Bantscheff, M., et al., Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol, 2011. 29(3): p. 255-65.

Title: Kranke, B., et al., Epidemiological significance of bufexamac as a frequent and relevant contact sensitizer. Contact Dermatitis, 1997. 36(4): p. 212-5.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 2438-72-4
Tags:2438-72-4 Molecular Formula|2438-72-4 MDL|2438-72-4 SMILES|2438-72-4 Bufexamac